Trinitrotoluene (TNT)

01/01/2023 - "TNT is also beneficial for distant rectal cancer patients who have need for organ preservation. "
12/01/2022 - "[A Case of Locally Advanced Rectal Cancer Treated Successfully with TNT]."
04/25/2019 - "Pathological findings revealed that 24 cases (27.6%) had TRG 0, 20 (23.0%) had TRG 1, 30 (34.5%) TRG 2, and 13 (14.9%) TRG 3. Conclusion: TNT is safe and has good short-term efficacy for locally advanced rectal cancer patients with high risk factors. "
11/01/2018 - "TNT is effective and safe in patients with locally advanced rectal cancer with high risk factors. "
01/01/2023 - "Improved response rates after TNT offers an attractive option to explore organ preservation in selective patients with locally advanced rectal cancer."

09/14/2023 - "TNT treatment significantly inhibited the PSMA (+) tumor growth and overall survival significantly improved (median survival time increase by 103%, p < 0.001). "
09/14/2023 - "In vivo, PSMA-expressing tumors in mice receiving TNT treatment demonstrated a significantly greater extent of apoptosis (78.45 ± 9.3%, p < 0.01) compared to the other groups. "
01/01/2023 - "The initial consensus from TNT studies was that pathological complete response, pathological response of the main tumor, and local control are more favorable at TNT than at CRT. "
07/06/2022 - "The purpose of this study is to understand how macrophages influence the TNT formation in cancer cells. "
11/29/2019 - "Recent studies showed that non-neoplastic cells can transfer mitochondria along tunneling nanotubes (TNT) and rescue damaged target cancer cells. "

01/01/2022 - "This meta-analysis was performed to evaluate the efficacy of TNT in terms of pathological complete remission (pCR), nCRT or surgical complications, R0 resection, local recurrence, distant metastasis, disease-free survival (DFS) and overall survival (OS) in LARC. "
01/01/2022 - "Statistical analyses revealed that, compared with standard CRT, TNT significantly improved OS (hazard ratio [HR]=0.77, 95% confidence interval [CI]=0.65-0.90, I 2 = 30%, P = 0.17), DFS (HR = 0.85, 95% CI = 0.74-0.97, I² = 11%, P = 0.35), distant metastases-free survival (DMFS, HR = 0.76, 95% CI = 0.65-0.90, I² = 0%, P = 0.50), pathological complete response rate (pCR, OR = 1.89, 95% CI = 1.61-2.22, I² = 0%, P = 0.47), and R0 resection rate (OR = 1.33, 95% CI = 1.07-1.67, I² = 16%, P = 0.28), but local recurrence-free survival (LRFS, HR = 1.12, 95% CI = 0.90-1.39, I² = 4%, P = 0.37). "
04/30/2023 - "Enthusiasm for delivering TNT for patients with LARC is increasing in light of the results of published randomized phase III trials, which show a doubling of the pCR rate and a significant reduction in the risk of subsequent metastases. "
04/01/2023 - "TNT was safe and feasible as it improved pCR and survival outcomes, and reduced the risk of distant metastasis compared with standard CRT. "
01/01/2023 - "TNT also improved rates of distant metastasis compared with LCRT (HR 0.81, 0.69 to 0.97). "

11/28/1994 - "A blinded prospective multicentre study representing 298 patients who on admission were suspected of acute myocardial infarction (AMI) to the coronary care units of six Scandinavian hospitals was undertaken to assess the diagnostic performance and prognostic efficacy of a new cardiospecific TnT immunoassay. "
11/01/1993 - "A blinded prospective multicentre study representing 298 patients suspected of having acute myocardial infarction (AMI), and admitted to the coronary care units of six Scandinavian Hospitals was undertaken to assess the diagnostic performance and prognostic efficacy of a new cardiospecific TnT immunoassay. "
01/01/2020 - "CRT postconditionging improved cardiac function, reduced serum LDH activity and TnT content, and limited myocardial infarct size after myocardial I/R injury in rat. "
01/01/2023 - "Using published studies (hs-cTnT study n = 1937, RAPID-TnT study n = 3270) and the Fourth Universal Definition of Myocardial Infarction (MI), index presentations of patients with hs-cTnT concentrations 5-14ng/L were classified as 'non-elevated' (NE). "
07/15/2008 - "Working heart preparations were employed to study rat acute myocardial infarction and transgenic mouse hearts over-expressing the N-terminal truncated cardiac TnT (cTnT-ND). "

01/01/2022 - "The improved pathologic complete response rate with TNT compared to short course RT or chemoradiation alone suggests proceeding to surgery might result in overtreatment, lending support to a watch-and-wait option for patients with a goal for nonoperative management if a clinical complete response is achieved. "
01/01/2017 - "Because the studies have largely focused on pathologic outcomes (primarily pathologic complete response rates), ongoing phase 2 and 3 trials are now underway assessing the long-term disease-related outcomes with TNT. "
06/30/2023 - "Fourteen percent of TNT patients and 5.8% of perioperative patients achieved a pathologic complete response (P=0.6). "
12/01/2022 - "We examined the role of TNT, in addition to other pre-operative factors, as a predictor for pathologic complete response (pCR). "
01/01/2022 - "RFS for patients in the watch-and-wait cohort at 12 months from completion of TNT more closely resembled patients who had undergone surgery and had a pathologic complete response than the watch-and-wait cohort at 3 months from completion of TNT. "